| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD79B |
| Uniprot No | P40259 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-159aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMARSEDR YRNPKGSACS RIWQSPRFIA RKRGFTVKMH CYMNSASGNV SWLWKQEMDE NPQQLKLEKG RMEESQNESL ATLTIQGIRF EDNGIYFCQQ KCNNTSEVYQ GCGTELRVMG FSTLAQLKQR NTLKD |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD79B重组蛋白的示例参考文献(内容为虚构，仅供格式参考)：
1. **文献名称**：*Structural and Functional Analysis of Recombinant CD79B in B-Cell Receptor Signaling*
**作者**：Smith A, et al.
**摘要**：该研究通过重组表达CD79B蛋白，解析其胞内结构域与酪氨酸激酶的相互作用，揭示了其在B细胞受体(BCR)信号转导中的关键调控机制。
2. **文献名称**：*CD79B Mutations and Their Impact on Recombinant Protein Stability in Lymphoma*
**作者**：Chen L, et al.
**摘要**：文章利用重组CD79B蛋白模型，分析弥漫大B细胞淋巴瘤(DLBCL)中CD79B突变对蛋白稳定性的影响，为靶向治疗提供分子基础。
3. **文献名称**：*Recombinant CD79B as a Tool for Developing B-Cell-Specific Antibody Therapeutics*
**作者**：Kim J, et al.
**摘要**：研究通过重组CD79B蛋白筛选特异性抗体，验证其在抗体药物偶联物(ADC)中的潜在应用，增强对B细胞恶性肿瘤的靶向性。
4. **文献名称**：*Expression and Purification of CD79B Recombinant Protein for Immunological Studies*
**作者**：Wang Y, et al.
**摘要**：报道了一种高效重组CD79B蛋白的真核表达系统，并优化纯化流程，为BCR信号通路的功能研究提供可靠工具。
---
**注意**：以上文献为示例，实际文献需通过PubMed、Web of Science等学术平台检索。
CD79B, a key component of the B-cell receptor (BCR) complex, is a transmembrane protein encoded by the CD79B gene. It pairs with CD79A to form a heterodimer that associates with membrane-bound immunoglobulins (IgM/IgD) on B cells, playing a critical role in BCR signal transduction. This signaling is essential for B-cell development, antigen recognition, and immune response regulation. CD79B contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, which recruits kinases like SYK to initiate downstream signaling cascades.
Recombinant CD79B protein refers to the engineered form of this protein produced in vitro using expression systems such as mammalian cells, bacteria, or yeast. Its production typically involves cloning the CD79B gene into expression vectors, followed by purification via affinity chromatography. Recombinant CD79B retains functional domains, enabling its use in structural studies, antibody development, and mechanistic research. For instance, it helps elucidate interactions within the BCR complex or screen therapeutic agents targeting B-cell malignancies.
In clinical contexts, CD79B mutations are linked to B-cell disorders, including diffuse large B-cell lymphoma (DLBCL). Recombinant CD79B facilitates studies on pathogenic mutations and serves as a tool for developing antibody-drug conjugates (ADCs) like polatuzumab vedotin, which targets CD79B-expressing cancers. Additionally, it aids in diagnosing autoimmune diseases by detecting autoantibodies against BCR components. Quality control assays (e.g., SDS-PAGE, Western blot) ensure recombinant CD79B retains native conformation and bioactivity. Overall, recombinant CD79B is a vital reagent for advancing both basic immunology research and therapeutic innovations in hematologic malignancies.
×
